ALAN BRYSON: Open Payments
NPI 1740675487 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$281 in 15 payments from 7 companies in 2025. Trend: 2023 $590 · 2024 $454 · 2025 $281
Food & beverage: $281
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $53 |
| Averitas Pharma Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| ABBVIE INC. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Kerendia, QUTENZA, Ozempic, JARDIANCE, SPRAVATO, LINZESS, FARXIGA.
Industry payments across MS — which companies pay providers there.
